Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
MOCLOBEMIDE
Meda Health Sales Ireland Limited
N06AG02
MOCLOBEMIDE
150 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
Monoamine oxidase A inhibitors
Transfer Pending
2009-01-23
Package leaflet: Information for the user MANERIX 150MG FILM-COATED TABLETS Moclobemide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. The name of your medicine Manerix 150mg Film-coated Tablets, which will be called Manerix Tablets throughout this leaflet. WHAT IS IN THIS LEAFLET: 1. What Manerix tablets are and what they are used for 2. What you need to know before you take Manerix tablets 3. How to take Manerix tablets 4. Possible side effects 5. How to store Manerix tablets 6. Contents of the pack and other information 1. WHAT MANERIX TABLETS ARE AND WHAT THEY ARE USED FOR Manerix tablets contain the active ingredient moclobemide which belongs to a group of medicines called monoamine oxidase inhibitors. Manerix tablets are used for the treatment of moderate or severe depression. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MANERIX TABLETS. DO NOT TAKE MANERIX TABLETS: - If you are taking pethidine ( a painkiller) - If you are taking selegiline ( a treatment for Parkinson’s disease) - If you are taking bupropion (an antidepressant) - If you are taking medicines for severe headaches (triptans) - If you are taking tramadol - If you are taking dextromethorphan (cough suppressant) - If you are t Pročitajte cijeli dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Manerix 150 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150mg moclobemide. Each tablet contains 140.6 mg of lactose. For a full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM Film coated tablets Oblong pale yellow tablet with ‘150’ printed on one face, scored on the reverse. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of moderate or severe depression. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults The initial daily dose is 300mg usually in two to three divided doses. The effects should usually occur within two to three weeks. If this response is inadequate the dose may be increased to a maximum of 600mg daily. Depending on response the dosage may be reduced slowly to as low as 150mg daily after four weeks. If no response occurs, treatment should be discontinued. The dose should not be raised until after the first week, as bioavailability increased during this period. Treatment should continue for at least 4-6 weeks in order to assess the efficacy of the drug. It is generally recommended that treatment should be continued until the patient has been free of symptoms for four to six months and then gradually tapered off. Older People Older patients do not require a special dose adjustment of Manerix. Children In view of the lack of clinical data available, Manerix is not recommended for use in children. Renal impairment Patients with reduced renal function do not require a special dose adjustment of Manerix. Hepatic impairment When hepatic metabolism is severely impaired by hepatic disease or a drug that inhibits microsomal mono-oxygenase activity (e.g. cimetidine), normal plasma levels are achieved by reducing the da Pročitajte cijeli dokument